Atara Biotherapeutics (ATRA) shares were down more than 40% in Thursday trading after the company reported "compliance issues" involving a third-party manufacturing facility for Ebvallo, a treatment for patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease.
The US Food and Drug Administration issued a complete response letter for Atara's biologics license application for Ebvallo, with the letter solely focusing on pre-license "inspection findings" involving the manufacturing plant, the company said.
No additional clinical trials were sought for FDA approval of Ebvallo and the agency did not identify any deficiencies in the manufacturing process, the clinical efficacy, or clinical safety data in the BLA, the company said.
Atara Chief Executive Cokey Nguyen said the BLA will be resubmitted once the third-party manufacturer issues have been addressed.
Price: 7.58, Change: -5.58, Percent Change: -42.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.